These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23667615)

  • 1. Inhaled steroids modulate extracellular matrix composition in bronchial biopsies of COPD patients: a randomized, controlled trial.
    Kunz LI; Strebus J; Budulac SE; Lapperre TS; Sterk PJ; Postma DS; Mauad T; Timens W; Hiemstra PS;
    PLoS One; 2013; 8(5):e63430. PubMed ID: 23667615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.
    Lapperre TS; Snoeck-Stroband JB; Gosman MM; Jansen DF; van Schadewijk A; Thiadens HA; Vonk JM; Boezen HM; Ten Hacken NH; Sont JK; Rabe KF; Kerstjens HA; Hiemstra PS; Timens W; Postma DS; Sterk PJ;
    Ann Intern Med; 2009 Oct; 151(8):517-27. PubMed ID: 19841453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial.
    Snoeck-Stroband JB; Lapperre TS; Sterk PJ; Hiemstra PS; Thiadens HA; Boezen HM; Ten Hacken NH; Kerstjens HA; Postma DS; Timens W; Sont JK;
    PLoS One; 2015; 10(12):e0143793. PubMed ID: 26659582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Airway epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease.
    Shukla SD; Sohal SS; Mahmood MQ; Reid D; Muller HK; Walters EH
    Int J Chron Obstruct Pulmon Dis; 2014; 9():853-61. PubMed ID: 25143722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central airways remodeling in COPD patients.
    Pini L; Pinelli V; Modina D; Bezzi M; Tiberio L; Tantucci C
    Int J Chron Obstruct Pulmon Dis; 2014; 9():927-32. PubMed ID: 25214779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study.
    van Grunsven P; Schermer T; Akkermans R; Albers M; van den Boom G; van Schayck O; van Herwaarden C; van Weel C
    Respir Med; 2003 Dec; 97(12):1303-12. PubMed ID: 14682412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study.
    Hattotuwa KL; Gizycki MJ; Ansari TW; Jeffery PK; Barnes NC
    Am J Respir Crit Care Med; 2002 Jun; 165(12):1592-6. PubMed ID: 12070058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse in FEV1 Decline After Steroid Withdrawal in COPD.
    Kunz LIZ; Postma DS; Klooster K; Lapperre TS; Vonk JM; Sont JK; Kerstjens HAM; Snoeck-Stroband JB; Hiemstra PS; Sterk PJ;
    Chest; 2015 Aug; 148(2):389-396. PubMed ID: 25836351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids.
    Kunz LI; Ten Hacken NH; Lapperre TS; Timens W; Kerstjens HA; van Schadewijk A; Vonk JM; Sont JK; Snoeck-Stroband JB; Postma DS; Sterk PJ; Hiemstra PS;
    Eur Respir J; 2017 Jan; 49(1):. PubMed ID: 28049170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
    Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness.
    Verhoeven GT; Hegmans JP; Mulder PG; Bogaard JM; Hoogsteden HC; Prins JB
    Thorax; 2002 Aug; 57(8):694-700. PubMed ID: 12149529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early intervention with inhaled corticosteroids in subjects with rapid decline in lung function and signs of bronchial hyperresponsiveness: results from the DIMCA programme.
    den Otter JJ; van Schayck CP; Folgering HT; van den Boom G; Akkermans RP; van Weel C
    Eur J Gen Pract; 2007; 13(2):89-91. PubMed ID: 17534745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lung extracellular matrix protein landscape in severe early-onset and moderate chronic obstructive pulmonary disease.
    Joglekar MM; Bekker NJ; Koloko Ngassie ML; Vonk JM; Borghuis T; Reinders-Luinge M; Bakker J; Woldhuis RR; Pouwels SD; Melgert BN; Timens W; Brandsma CA; Burgess JK
    Am J Physiol Lung Cell Mol Physiol; 2024 Sep; 327(3):L304-L318. PubMed ID: 38915286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.
    Paggiaro PL; Dahle R; Bakran I; Frith L; Hollingworth K; Efthimiou J
    Lancet; 1998 Mar; 351(9105):773-80. PubMed ID: 9519948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled trial of inhaled fluticasone propionate in moderate to severe COPD.
    Thompson WH; Carvalho P; Souza JP; Charan NB
    Lung; 2002; 180(4):191-201. PubMed ID: 12391509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
    Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
    Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
    Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
    Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
    Aaron SD; Vandemheen KL; Fergusson D; Maltais F; Bourbeau J; Goldstein R; Balter M; O'Donnell D; McIvor A; Sharma S; Bishop G; Anthony J; Cowie R; Field S; Hirsch A; Hernandez P; Rivington R; Road J; Hoffstein V; Hodder R; Marciniuk D; McCormack D; Fox G; Cox G; Prins HB; Ford G; Bleskie D; Doucette S; Mayers I; Chapman K; Zamel N; FitzGerald M;
    Ann Intern Med; 2007 Apr; 146(8):545-55. PubMed ID: 17310045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue.
    Gizycki MJ; Hattotuwa KL; Barnes N; Jeffery PK
    Thorax; 2002 Sep; 57(9):799-803. PubMed ID: 12200525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.